Three-dimensional (3D) bioprinting is used to combine cells, growth factors, and biomaterials to manufacture biomedical parts that mimic the natural properties of the tissue. 3D Bioprinting is a process where bioink — consisting of living cells — and biomaterials and structural scaffolds are deposited on the surface to produce 3D structures.
The 3D bioprinting market was valued at USD 970.5 million in 2019 and is expected to grow with a CAGR of 18.7% during the forecast period.
Biomimetic physical models of patient tissues can be built when used in combination with medical imaging modalities. 3D bioprinting typically uses the layer-by-layer process to deposit materials and create tissue-like structures that are later used in the fields of medical and tissue engineering. Bioprinting covers a wide array of biomaterials and can be used to print tissues and organs to test drugs. Moreover, 3D bioprinting is now able to print scaffolds, which can be used to reconstruct joints and ligaments.
The 3D bioprinting market is projected to witness exponential growth on account of groundbreaking developments in the healthcare and pharmaceutical industries. 3D bioprinting is an active area of research composed of different biologically applied processing and assembly methods, including direct writing, photolithography, microstamping, extrusion, laser writing, stereolithography, electro-printing, microfluidics, and inkjet deposition.
Healthcare is one of the leading users of 3D bioprinting, and rising investment in healthcare applications provides an impetus to the market growth. Apart from this, 3D bioprinting is extensively used by cosmetic companies for printing tissue and hair follicles, especially in Europe, where cosmetic animal testing is prohibited since 2013. Additionally, several companies are heavily investing in R&D activities to develop innovative products. Organovo, a scientific laboratory, and research firm is at the forefront in 3D bioprinting. Increasing demand for high-performance tissue models,
and widespread use of regenerative therapies, such as transplantation and tissue generation, drives the market growth.
Rising incidence of chronic diseases, such as heart and kidney failures, increasing the geriatric population, and a limited number of organ donors, prompt the need for effective 3D bioprinting. Technological advancement in the healthcare industry and growing investments in R&D activities provide an impetus to the market growth. Recently, in January 2019, the Institute for Technology Inspired Regenerative Medicine collaborated with Aspect Biosystems, a Canadian company, to use 3D printing in the field of regenerative medicine.
The magnetic levitation segment is projected to exhibit the fastest growth during the forecast period. The syringe-based segment, on the other hand, holds the largest market share. Increasing adoption of 3D bioprinting technique by innovators drives the segment growth. 3D magnetic levitation-based bio-printers have the capability to solve more than 80% of current failures with improved speed, functionality, and precision. These bio-printers are extensively used for printing vascular muscles, toxicity screening, and regeneration of human cells. For instance, BioAssay developed a tissue-like structure using magnetic levitation.
By the application, the medical segment is further divided into tissue generation, organ development, prosthetics and implants, and medical pills. The medical pills segment holds over 35% of the market share. Medicinal pill is the latest market advancement and is projected to witness the fastest growth during the forecast period. Increasing demand for medicines and rising awareness regarding the advantages of 3D bioprinting drives the segment.
The COVID-19 outbreak prompts the need for new diagnostic and therapeutic measures to overcome infectious diseases across the globe. The technique can be applied by tissue engineers in the virology and epidemiological testing. This highlights the important tissue engineering developments relevant to the current pandemic, including in vitro modeling systems, vaccine technology, and small-molecule drug delivery. For instance, CLECELL’s innovative bioprinting technique has the potential to become a testbed for vaccine development.
North America dominates the 3D bioprinting market as the region is backed by the presence of prominent market players, robust healthcare infrastructure, and high disposable income. The U.S. and Canada are at the forefront of the 3D bioprinting market on account of the extensive research activities conducted in the field.
In October 2018, The U.S. FDA awarded a USD 2.5 million grant to the top five bio-manufacturing R&D centers, which include the Institute of Technology in Georgia, University of Carnegie Mellon, Harvard University, University of Rutgers, and Institute of Technology in Massachusetts. In March 2016, a U.S.-based pharmaceutical firm, Aprecia Pharmaceutical, became the first company in the world to obtain the FDA approval for Spritam, a bioprinted 3D drug.
Asia-Pacific is projected to grow with the highest CAGR during the forecast period on account of the presence of the large target population seeking organ transplantation in India, China, Japan, and Southeast Asia. Increasing awareness regarding 3D printing technology, rising foreign investment influx, and supportive government policies drive the regional market growth. For instance, China launched ‘Made in China 2025’ to promote the use of advanced technology in the field of 3D printing. The Ministry of Industry and Information Technology of China released a dedicated program for the industry's commercialization.
|Market Size||USD in Billion By 2030|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|
|Segments Covered||by Technology (Magnetic Levitation) Application (Medical, Dental, Biosensors, Food, and Animal Products)|
|Geographies Covered||North America, Europe, Asia-Pacific, LAME and Rest of the World|
|Key Companies Profiled/Vendors||Organovo Holding, Inc., Luxexcel Group B.V., TeVido BioDevices, LLC, 3Dynamics Systems Ltd., Cyfuse Biomedical K.K., Aspect Biosystems Ltd., Stratasys Ltd., Voxeljet A.G., Bio3D Technologies Pte. Ltd., Materialise N.V., Envision TEC|
|Key Market Opportunities||The Medical Devices Industry'S Substantial Growth Fuels The 3D Bioprinting Market|